Healthcare
Novartis AG(NVSEF)
Live Price
Offline$145.00
+0.00% today
1Y Change
+29.97%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $282.81B
- Revenue Growth
- +10.4%
- EPS Growth
- +27.7%
- Dividend Yield
- 3.2%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Novartis AG (NVSEF) is a Healthcare stock with a market cap of $282.81B and listed on OTC. The stock last traded around $145.00 and up 30.0% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +10.4%, EPS growth of +27.7%, a dividend yield of 3.2%. What stands out right now is revenue +10.4%, EPS +27.7%, free cash flow +33.5% with operating margin 29.9% and ROIC 14.9%. The dividend matters to the case here, with a current yield around 3.2%. Valuation sits in the middle of the pack at P/E 21.0 and price/sales 5.1. Stock Foundry combines NVSEF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+10.4% vs +7.6% peer median
Operating Margin
Above sector median
+29.9% vs +19.4% peer median
P/E
Below sector median
21.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 28, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +10.4% and EPS at +27.7%, with operating margin around 29.9%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 3.2%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.1% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 28, 2026 | โ | +0.0% | -0.7% | +4.1% |
2026 Feb 4, 2026 | +2.0% | +0.0% | +3.8% | +3.4% |
2025 Jul 17, 2025 | -12.3% | +0.0% | -2.9% | -2.7% |
Benchmark Edge
NVSEF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NVSEF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NVSEF Max Drawdown
-17.69%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NVSEF and SPY.
Company Overview
Novartis AG
Other OTC
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
- Leadership
- Vasant Narasimhan
- IPO Date
- Apr 26, 2010
- Employees
- 75.9k
- Street Address
- Lichtstrasse 35
- Mailing
- Basel, 4056
- Region
- Basel, CH
- Reporting Currency
- USD
- Investor Line
- 41 61 324 1111
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 21.0
- EV/EBITDA
- 14.8
- Price/Sales
- 5.1
- Price/Book
- 7.3
Growth
- Revenue
- +10.4%
- EPS
- +27.7%
- Free Cash Flow
- +33.5%
Profitability
- Gross Margin
- 75.1%
- Operating Margin
- 29.9%
- Net Margin
- 24.3%
- ROE
- 31.5%
- ROIC
- 14.9%
Balance Sheet
- Debt/Equity
- 1.22
- Current Ratio
- 0.85
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.